EVELO BIOSCIENCES INC's ticker is EVLO and the CUSIP is 299734103. A total of 43 filers reported holding EVELO BIOSCIENCES INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $1,000 | -98.1% | 265 | -98.3% | 0.00% | – |
| Q1 2022 | $53,000 | -44.8% | 15,765 | 0.0% | 0.00% | – |
| Q4 2021 | $96,000 | +37.1% | 15,765 | +57.8% | 0.00% | – |
| Q3 2021 | $70,000 | -81.3% | 9,988 | -63.4% | 0.00% | – |
| Q2 2021 | $375,000 | +72.0% | 27,291 | +33.8% | 0.00% | – |
| Q1 2021 | $218,000 | +66.4% | 20,400 | +88.9% | 0.00% | – |
| Q4 2020 | $131,000 | +129.8% | 10,800 | 0.0% | 0.00% | – |
| Q3 2020 | $57,000 | +7.5% | 10,800 | 0.0% | 0.00% | – |
| Q2 2020 | $53,000 | +29.3% | 10,800 | 0.0% | 0.00% | – |
| Q1 2020 | $41,000 | -6.8% | 10,800 | 0.0% | 0.00% | – |
| Q4 2019 | $44,000 | -33.3% | 10,800 | 0.0% | 0.00% | – |
| Q3 2019 | $66,000 | -32.0% | 10,800 | 0.0% | 0.00% | – |
| Q2 2019 | $97,000 | +12.8% | 10,800 | 0.0% | 0.00% | – |
| Q1 2019 | $86,000 | -9.5% | 10,800 | +47.9% | 0.00% | – |
| Q4 2018 | $95,000 | +6.7% | 7,300 | 0.0% | 0.00% | – |
| Q3 2018 | $89,000 | +3.5% | 7,300 | 0.0% | 0.00% | – |
| Q2 2018 | $86,000 | – | 7,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Mayo Clinic | 484,953 | $1,823,000 | 4.61% |
| Flagship Pioneering Inc. | 18,233,403 | $68,558,000 | 3.21% |
| HARBOURVEST PARTNERS LLC | 1,763,505 | $6,622,000 | 3.20% |
| Alphabet Inc. | 1,060,495 | $3,982,000 | 0.26% |
| Larson Financial Group LLC | 20,042 | $75,000 | 0.05% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 133,500 | $501,000 | 0.01% |
| CREDIT SUISSE AG/ | 1,500,117 | $5,633,000 | 0.01% |
| FMR LLC | 3,220,853 | $12,094,000 | 0.00% |
| VICTORY CAPITAL MANAGEMENT INC | 177,856 | $668,000 | 0.00% |
| Legal & General Group Plc | 1,522 | $6,000 | 0.00% |